Trending with Impact: New Immunotherapy Peptide Cocktail for Multiple Myeloma



October 7, 2021

  • Share
  • Oncotarget published this trending research paper on September 28, 2021, entitled, "Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma" by researchers from the Department of Immunology, Mayo Clinic, Scottsdale, AZ; Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, AZ/Rochester, MN; Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ. Abstract: Multiple Myeloma (MM) patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses. Here we evaluate the possibility of adoptive cell transfer (ACT) by generating ex vivo T cells from peripheral blood mononuclear cells (PBMCs) isolated from MM patients by employing our previously devised protocols. We designed peptides from antigens (Ags) including cancer testis antigens (CTAs) that are over expressed in MM. We exposed PBMCs from different healthy donors (HDs) to single peptides. We observed reproducible Ag-specific cluster of differentiation 4+ (CD4+) and CD8+ T cell responses on exposure of PBMCs to different single peptide sequences. These peptide sequences were used to compile four different peptide cocktails. Naïve T cells from PBMCs from MM patients or HDs recognized the cognate Ag in all four peptide cocktails, leading to generation of multiclonal Ag-specific CD4+ and CD8+ effector and central memory T (TEM and TCM, respectively) cells which produced interferon-gamma (IFN-γ), granzyme B and perforin on secondary restimulation. Furthermore, this study demonstrated that immune cells from MM patients are capable of switching metabolic programs to induce effector and memory responses. Multiple peptides and cocktails were identified that induce IFN-γ+, T1-type, metabolically active T cells, thereby paving the way for feasibility testing of ACT in phase I clinical trials. Press release - Sign up for free Altmetric alerts about this article - DOI - Full text - Correspondence to - Sandra J. Gendler - Keywords - multiple myeloma, cellular therapy, CD4/CD8 T cells, peptides, immunotherapy About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit or connect with: SoundCloud - Facebook - Twitter - YouTube - LinkedIn - Pinterest - Reddit - Oncotarget is published by Impact Journals, LLC please visit or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    Cancer ResearchImmunology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.